InVivoMAb anti-human GPC-2

Bio X Cell

InVivoMAb anti-human GPC-2

7

Research Use Only

Monoclonal

CT3

4-11 mg/ml

Mouse

IgG1

The CT3 monoclonal antibody reacts with tumor-associated exons 3 and 10 of glypicans-2 (GPC2), a cell surface glycoprotein differentially expressed in neuroblastomas compared with normal tissues. GPC2 is also known as cerebroglycan, and it is one of the six members of glypicans, which are glycosylphosphatidylinositol (GPI)-anchored cell surface coreceptors. GPCs interact with multiple growth factors and chemokines to regulate the processes of cell proliferation, death, and differentiation. N-myc proto-oncogene protein (MYCN) controls the expression of GPC2 at its transcriptional level. Enhanced GPC2 expression in neuroblastoma promotes the Wnt/β-catenin pathway and upregulates N-Myc expression to drive tumorigenesis. Among various GPC2 antibodies, the CT3 antibody is known to recognize over-expressed GPC2 in neuroblastoma, and it does not show reactivity in normal peripheral nerves or other normal tissues. The CT3 antibody does not bind to any other GPCs. CT3-based CAR T cells directed towards GPC2 show potent anti-tumor activity in vivo in preclinical mouse models of localized as well as metastatic neuroblastoma. GPC2 antibody-drug conjugates (e.g., D3-GPC2-PBD) have been documented to deliver cytotoxicity in neuroblastoma cell lines and robust antitumor effects in human neuroblastoma patient-derived xenograft (PDX) in vivo models.

Human

2°C to 8°C

12352203